DR. BIRRER: We thought it might be helpful for everybody to know who is sitting next to them. I have been asked to introduce a number of individuals, starting with the participants from the Gynecologic Oncology Group.

As Larry said, Dr. Disaia could not attend, due to scheduling conflict, but essentially all the senior leadership from GOG is here.

Dr. Copeland is Vice-Chair. We have the Chair of the protocol committee, Tate Thigpen, his two Co-Chairs, Dr. Thomas and Dr. Stehman. We have the Director of the Administrative Office in Philadelphia, Mr. Jack Kellner.

We have the leaders of the ovary committee. Bob Mannel is Chair, and his Co-Chair is Gini Fleming. Developmental therapeutics, the Chair is Mike Bookman, who also represents the Fox-Chase SPORE, and his Co-Chair is Paula Fracasso.

I am Chair of the committee of experimental medicine. My two Co-Chairs are Bill Beck and Tom Hamilton. We have the Director of the GOG tissue bank here. That would be Steve Qualman.

The committee that oversees the tissue bank is the tissue utilization subcommittee, which is chaired by Mike Seiden and co-chaired by Jeff Boyd, back there with the tan.

We have full representation from the GOG Statistical Office. That would include its Director, Mark Brady, and members Alan Hutson, Cathleen Darcy, Zoe Miner and Dan Gaile.

In addition to those individuals, we have essentially everybody that we could identify within the group who has a keen interest in either laboratory based or clinical aspects of ovarian cancer research. I will go through that list, if you could just acknowledge yourself.

Carol Aghajanian from Memorial, Deb Armstrong, Doris Benbrook, Carol Brown, Bob Burger, George Couckos, Bill Creasman, Agustan Garcia, Ben Greer, Steve Howell, Brad Monk, Bob Park, Peter Rose, Angeles Alvarez Secord, and David Spriggs.

In addition, we have representatives from the NCI intramural program, and it would include, of course, myself, Kathy Kelly, who is not here yet, Elise Kohn, Herb Kotz.

Then we also involved recipients of the Director's Challenge Grants, because are the very large grants that were involved in genomic analysis. That would include myself, Jeff Boyd, and Steve Johnson. That does mine. Thank you.

TOP